Skip to search formSkip to main contentSkip to account menu

Antibody-Drug Conjugate SC16LD6.5

Known as: Anti-SC16 ADC SC16LD6.5, SC16LD6.5 
An antibody-drug conjugate (ADC) containing an antibody directed against the scr-like kinase Fyn3 (SC-16), conjugated to the cytotoxic agent D6.5… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
DLL3 is overexpressed in neuroendocrine prostate cancer and is a potential therapeutic target. Lessons from one tumor help with… 
Review
2019
Review
2019
Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges
Small-cell lung cancer (SCLC) is an aggressive disease with still limited therapeutic options. Despite being both a chemo- and… 
Highly Cited
2017
Highly Cited
2017
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade… 
2017
2017
Abstract 3093: Expression of DLL3 in metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas as potential indications for rovalpituzumab tesirine (Rova-T; SC16LD6.5…
Expression of DLL3 was examined in additional tumor types, as it was found to be highly expressed in tumor-initiating cells (TIC… 
2016
2016
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).
LBA8505Background: SCLC remains among the most deadly of malignancies. Rovalpituzumab tesirine is a first-in-class ADC comprised… 
2016
2016
Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse
  • S. Dylla
  • Molecular & Cellular Oncology
  • 2016
  • Corpus ID: 41908753
ABSTRACT Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug… 
Highly Cited
2015
Highly Cited
2015
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers… 
2003
2003
Formation and relaxation of coherency strain in the nickel-base superalloy SC16.
An in situ study of the kinetics of relaxation of the gamma-gamma' lattice mismatch in the single-crystal Ni-base superalloy SC16… 
2003
2003
Simulation of solidification and heat treatment of nickel-base superalloy SC16
Thermodynamic equilibrium and Gulliver – Scheil as well as diffusion calculations using the DICTRA program have been made to… 
Highly Cited
1995
Highly Cited
1995
First-principles pseudopotential study of the phase stability of the III-V semiconductors GaAs and AlAs.
A first-principles pseudopotential study of the phase stability of the III-V semiconductors GaAs and AlAs is reported. For both… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)